nor risk factors for HEV. Although HEV serology was initially equivocal, IgG and IgM later became positive with detectable PCR. His ALT normalised and HEV-PCR became undetectable four weeks later.

Discussion/Conclusion HEV appears to be a self-limiting-asymptomatic illness in HIV+ MSM with good CD4 counts. HEV may be sexually transmitted in populations with increasing STI rates. HEV should be considered a potential cause of elevated liver enzymes in HIV+ patients.

### P35 ARE TESTICULAR MIXED GERM CELL TUMOURS ASSOCIATED WITH HEPATITIS C (HCV) IN HIV INFECTED MEN WHO HAVE SEX WITH MEN?

David Atef*, Daniel Richardson. BSUM NHS Trust, Brighton, UK

10.1136/sextrans-2015-052126.79

**Background/introduction** HCV infection and testicular germ-cell tumours are indicator diseases for HIV-testing in BASHH-guidelines. There is little data on the association of testicular tumours in MSM with HIV.

**Aim(s)/objectives** We describe 2 MSM with treated HIV-Hepatitis C co-infection who were both subsequently diagnosed with mixed-germ-cell testicular tumours.

**Case details** Patient-1 is a 51-year-old MSM, diagnosed with HIV in 2004 on Atripla since 2010. In May 2012, routine ALT = 186 and positive HCV-RNA (genotype 1). This was treated with 48-weeks of pegylated-interferon/ribavirin. He had a sustained-viral-response (SVR). Two years later, he presented to the STI-clinic with a four month history of testicular swelling. Ultrasound showed this to be likely malignant infiltration, AFP = 2484, LDH = 426, HCG = 5.9. After orchidectomy, histology demonstrated mixed germ cell tumour. He is in clinical/radiological remission. Patient-2 is a 41-year-old MSM diagnosed with HIV in 2004 on Atripla since 2010. That year, he presented with an E-Coli-UTI and testicular swelling. Ultrasound/orchidectomy found a mixed germ cell testicular tumour. Tumour markers were AFP = 16.5, LDH = 376, HCG = 16.5. He was treated with orchidectomy, bleomycin/etoposide/cisplatin and is in radiological/clinical remission.

**Discussion/conclusion** HIV infection and hepatitis C treatment are immunosuppressive and are potential causative factors in these HIV-MSM testicular germ-cell tumours. Early investigation of testicular swellings in men with HIV-Hepatitis C is important.

### P36 AUTOIMMUNE HEPATITIS IN A PATIENT WITH HIV AND HEPATITIS B CO-INFECTION ALONG WITH LATENT TB: A THERAPEUTIC DILEMMA

Nisha Pal, Mamatha Odhuru*, Noreen Desmond. Berkshire Healthcare Foundation Trust, Garden Clinic, Slough, Berkshire, UK

10.1136/sextrans-2015-052126.80

**Background/introduction** Liver disease is an important cause of morbidity and mortality in patients infected with HIV infection. Abnormal liver function tests are frequently encountered in these patients and often attributed to HAART. Autoimmune Hepatitis is a rare disease with unclear pathogenesis; several viruses have been proposed to act as triggering agents for the inflammatory process of the disease.

**Case presentation** We present a 46 year old Afro-Caribbean gentleman who presented with lethargy, weight loss and jaundice. He was diagnosed to be co-infected with HIV and Hepatitis B with a positive autoimmune screen. His persistently elevated liver enzymes warranted a liver biopsy which revealed interface hepatitis, necrosis with lymphocytes and plasma cell infiltrates with variable degree of fibrosis. A picture difficult to interpret in the light of HIV and Hepatitis B infections. His persistently high ALT made it challenging to initiate antiretroviral therapy and the need for steroids to suppress the autoimmune Hepatitis raised a concern regarding the reactivation of the latent TB infection as diagnosed by a positive IGRA test. A review of literature revealed 12 cases of HIV with AIH, but none co-infected with Hepatitis B.

**Conclusion** There are no clear guidelines for management of autoimmune Hepatitis in HIV and treatment is with immunosuppressive agents. A multidisciplinary approach helped in the management of this gentleman when stable on antiretroviral therapy and tapering doses of steroids, along with chemoprophylaxis against latent TB.